Literature DB >> 20603857

Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases.

M Karoui1, L Vigano, P Goyer, A Ferrero, A Luciani, M Aglietta, C Delbaldo, S Cirillo, L Capussotti, D Cherqui.   

Abstract

BACKGROUND: This study assessed the feasibility and outcomes of combined colorectal and hepatic resection as the first step of two-stage hepatectomy in patients with bilobar synchronous colorectal liver metastases.
METHODS: All patients with bilobar synchronous colorectal liver metastases who were considered for two-stage hepatectomy, combining resection of the primary tumour with the first stage of hepatectomy, between 2000 and 2008 were selected from a prospectively collected database at two institutions. Data were analysed retrospectively on an intention-to-treat basis.
RESULTS: Thirty-three patients were studied. Twenty patients received neoadjuvant chemotherapy. Combined colorectal resection and clearance of left-sided liver metastases was the first-stage procedure in all but one patient, in whom right clearance was performed. In 17 patients right portal vein ligation was undertaken at the same time. No patient died. Two patients had anastomotic leakage. Interval chemotherapy was given to 25 patients, five of whom also had percutaneous portal vein embolization. Twenty-five patients had the second-stage hepatectomy, but not eight patients with disease progression. There was one postoperative death after the second stage, and eight patients experienced morbidity. Median follow-up from the first stage was 28.7 months. Overall and disease-free survival rates for patients who completed the procedure were 80 and 44 per cent respectively at 3 years, and 48 and 22 per cent at 5 years.
CONCLUSION: In patients with bilobar synchronous colorectal liver metastases who are candidates for two-stage hepatectomy, combined resection of the primary tumour and first-stage hepatectomy reduces the number of procedures, optimizes chemotherapy administration and may improve outcome. Copyright 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20603857     DOI: 10.1002/bjs.7128

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  22 in total

1.  The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology.

Authors:  Aldo Rocca; Federica Cipriani; Paolo Delrio; Fulvio Calise; Luca Aldrighetti; Giulio Belli; Stefano Berti; Ugo Boggi; Vincenzo Bottino; Umberto Cillo; Matteo Cescon; Matteo Cimino; Francesco Corcione; Luciano De Carlis; Maurizio Degiuli; Paolo De Paolis; Agostino Maria De Rose; Domenico D'Ugo; Fabrizio Di Benedetto; Ugo Elmore; Giorgio Ercolani; Giuseppe M Ettorre; Alessandro Ferrero; Marco Filauro; Felice Giuliante; Salvatore Gruttadauria; Alfredo Guglielmi; Francesco Izzo; Elio Jovine; Andrea Laurenzi; Francesco Marchegiani; Pierluigi Marini; Marco Massani; Vincenzo Mazzaferro; Michela Mineccia; Francesco Minni; Andrea Muratore; Simone Nicosia; Riccardo Pellicci; Riccardo Rosati; Nadia Russolillo; Antonino Spinelli; Gaya Spolverato; Guido Torzilli; Giovanni Vennarecci; Luca Viganò; Leonardo Vincenti
Journal:  Updates Surg       Date:  2021-06-05

Review 2.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

3.  Liver angulometry: a simple method to estimate liver volume and ratios.

Authors:  Reza Kianmanesh; Tullio Piardi; Esther Tamby; Alina Parvanescu; Onorina Bruno; Elisa Palladino; Olivier Bouché; Simon Msika; Daniele Sommacale
Journal:  HPB (Oxford)       Date:  2013-03-08       Impact factor: 3.647

4.  A comparative study of patients with and without associated digestive surgery in a two-stage hepatectomy setting.

Authors:  Mattia Stella; Aurélien Dupre; Sylvie Chabaud; Alessandro Gandini; Pierre Meeus; Patrice Peyrat; Michel Rivoire
Journal:  Langenbecks Arch Surg       Date:  2012-09-29       Impact factor: 3.445

5.  Comparison of various surgical approaches for extensive bilateral colorectal liver metastases.

Authors:  Christoph Reissfelder; Nuh N Rahbari; L Urrutia Bejarano; Thomas Schmidt; Nikolas Kortes; Hans-Ulrich Kauczor; Markus W Büchler; Jürgen Weitz; Moritz Koch
Journal:  Langenbecks Arch Surg       Date:  2014-03-11       Impact factor: 3.445

Review 6.  Management of liver cancer. The Surgeon's point of view.

Authors:  Pierre Rabinel; Damien Dousse; Fabrice Muscari; Bertrand Suc
Journal:  Rep Pract Oncol Radiother       Date:  2017-03-23

7.  Laparoscopic Approach for Primary Colorectal Cancer Improves Outcome of Patients Undergoing Combined Open Hepatic Resection for Liver Metastases.

Authors:  Francesca Ratti; Marco Catena; Saverio Di Palo; Carlo Staudacher; Luca Aldrighetti
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

8.  Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections.

Authors:  Clarisse Eveno; Mehdi Karoui; Etienne Gayat; Alain Luciani; Marie-Luce Auriault; Michael D Kluger; Isabelle Baumgaertner; Laurence Baranes; Alexis Laurent; Claude Tayar; Daniel Azoulay; Daniel Cherqui
Journal:  HPB (Oxford)       Date:  2012-10-22       Impact factor: 3.647

9.  Is there new hope for patients with marginally resectable liver malignancies.

Authors:  Martin Loos; Helmut Friess
Journal:  World J Gastrointest Surg       Date:  2012-07-27

10.  Incidence and predictive factors of clinically relevant bile leakage in the modern era of liver resections.

Authors:  Antoine Guillaud; Claire Pery; Boris Campillo; Anne Lourdais; Laurent Sulpice; Sulpice Laurent; Karim Boudjema
Journal:  HPB (Oxford)       Date:  2012-10-04       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.